Multi-arm Star Polymer Carriers for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nitric oxide-releasing agents for cancer therapy face challenges due to dose-dependent carcinogenicity and non-specific tissue distribution, leading to toxicity in healthy tissues, and existing drug delivery systems are limited by stability and size constraints for effective targeting of tumors.
Innovation Solution
Development of multi-arm star polymers synthesized via reversible addition-fragmentation chain transfer (RAFT) polymerization, conjugated with nitric oxide prodrugs and chemotherapeutics like cisplatin, to create nanoconjugates that are biodegradable, water-soluble, and specifically targeted to tumors for controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nitric oxide-releasing agents are administered systemically for cancer therapy, then anti-cancer efficacy is improved, but toxicity in healthy tissues increases due to non-specific tissue distribution
Solution Approach 1:
The patent uses multi-arm star polymer carriers as intermediaries to deliver nitric oxide prodrugs and chemotherapeutics to tumor tissues. These polymer carriers accumulate in tumors through the enhanced permeability and retention (EPR) effect, enabling selective drug release at the tumor site while minimizing exposure to healthy tissues. The polymer acts as a mediator between the drug and the target tissue, resolving the contradiction between systemic efficacy and healthy tissue toxicity.
Solution Approach 2:
The patent achieves local concentration of drugs in tumor tissues through passive targeting via the EPR effect and active targeting using ligand-receptor interactions. The multi-arm star polymer carriers are designed to accumulate specifically in tumor tissues, creating high local drug concentration where needed while maintaining low systemic levels, thereby improving the therapeutic index and reducing toxicity to healthy organs.
2Reliability
If drug delivery systems use micelles and liposomes for targeted delivery, then tumor targeting is improved, but stability in the extravascular space is insufficient
Solution Approach 1:
The patent employs multi-arm star polymers as composite delivery vehicles that combine the advantages of micelles and liposomes while overcoming their limitations. These polymers feature a core-shell structure with hydrophobic cores for drug loading and hydrophilic shells for stability in biological environments. The multi-arm architecture provides structural rigidity and enhanced stability in the extravascular space compared to conventional micelles and liposomes, while maintaining effective tumor targeting capabilities.
3Stability of the object's composition
If dendrimers are used as drug delivery carriers, then stability and targeting are improved, but biodegradability is limited and water-insoluble drug capacity is restricted
Solution Approach 1:
The patent modifies the structural parameters of dendrimer-like carriers by using multi-arm star polymers with controllable arm numbers, molecular weights, and branch architectures. This allows optimization of the balance between stability and biodegradability. The polymers are designed with hydrolyzable ester bonds in the backbone that enable controlled degradation in the body, while the multi-arm structure provides sufficient stability during circulation and targeting. Additionally, the large surface area and tunable architecture enhance capacity for both water-soluble and water-insoluble drugs.
4Reliability
If nitric oxide is released at high concentrations to inhibit cancer cell proliferation, then anti-cancer activity is improved, but dose-dependent carcinogenicity increases
Solution Approach 1:
The patent achieves high local concentrations of nitric oxide at the tumor site through targeted delivery using multi-arm star polymer carriers, while maintaining low systemic levels. The carriers accumulate in tumors via the EPR effect and ligand-receptor interactions, enabling selective release of high doses of nitric oxide where cancer cells are present. This spatial differentiation of drug concentration resolves the contradiction between achieving effective anti-cancer activity and avoiding systemic carcinogenicity.
Solution Approach 2:
The multi-arm star polymer carriers serve as intermediaries that control the release kinetics and spatial distribution of nitric oxide. The polymers protect nitric oxide from premature decomposition during circulation and enable controlled release at the tumor site through enzymatic degradation or pH-triggered mechanisms. This intermediary approach allows delivery of therapeutically effective doses while minimizing exposure of healthy tissues to carcinogenic levels of nitric oxide.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multi-arm star polymer nanoconjugates provide sustained release of nitric oxide and platinum-based chemotherapeutics, enhancing tumor targeting and reducing systemic toxicity, with improved stability and lymphatic accumulation, effectively inhibiting cancer cell growth and metastasis.
Implementation Method 1
the multi-arm star polymer nanoconjugates provide sustained release of nitric oxide and platinum-based chemotherapeutics
Implementation Method 2
Multi-arm polymers can be synthesized under a broad range of conditions with low polydispersity using reversible addition-fragmentation chain transfer polymerization (RAFT)
Data Source
AI summary
A multi-arm, star-shaped polymer composition can be configured for drug delivery and imaging applications in vivo. The star polymer architecture can be synthesized using living radical polymerization techniques, including reversible addition-fragmentation chain transfer and macromolecular design via the interchange of xanthates with a broad range of reaction conditions and functional groups. The star-shaped polymeric carriers can be tailored for preferential delivery of chemotherapeutics into the tumor-draining lymphatics via subcutaneous, peritumoral or intratumoral injections. The carriers can be loaded with the chemotherapeutic agents from about 10% to about 25% w/w. In addition, the carriers can be loaded with imaging agents from about 5% to about 10% w/w. The molecular weights of the polymeric carriers can be about 40 kDa to about 130 kDa. The chemotherapeutics can be cisplatin, geldanamycin or nitric oxide-donating prodrugs. The imaging agent can be a near-infrared dye, such as IR820.